厄洛替尼治疗老年晚期非小细胞肺癌的疗效  

Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer

作　　者：孙长江[1] 张西志[1] 陈勇[1] 

机构地区：[1]苏北人民医院肿瘤科,江苏扬州225001

出　　处：《南方医科大学学报》2012年第12期1839-1840,F0003,共3页Journal of Southern Medical University

基　　金：中国高校医学期刊临床专项资金(11220262)

摘　　要：目的观察厄洛替尼治疗老年晚期非小细胞肺癌(NSCLC)的疗效与毒副反应。方法选取72例经病理学确诊的老年晚期(Ⅲ期或Ⅳ期)NSCLC患者,采用单药口服厄洛替尼150 mg,1次/d,直至出现不能耐受的不良反应或PD时中止治疗。观察厄洛替尼的临床疗效、不良反应,同时对影响厄洛替尼疗效的临床因素进行分析。结果72例NSCLC患者中,CR 1例(1.39%),PR 20例(27.78%),SD 31例(43.06%),疾病控制率(CR+PR+SD)72.22%。中位随访时间17个月(4-32个月),全组患者中位生存期14.5个月(6.5-28.3个月),中位疾病无进展生存10.6个月(5-16.5个月)。其中女性、腺癌及不吸烟的患者接受厄洛替尼治疗的疗效明显高于男性、鳞癌及吸烟患者(P<0.05)。是否出现皮疹与治疗疗效之间未见显著联系(P>0.05)。相关不良反应以皮疹、腹泻、转氨酶升高、恶心呕吐为主,多为轻度。结论厄洛替尼治疗老年NSCLC具有较好的疗效,毒性可耐受。Objective To observe the curative and adverse side effects of erlotinib in elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods Seven-two elderly patients with pathologically confirmed NSCLC in advanced stage （III or W） received treatment with oral erlotinib at the daily dose of 150 mg, and the treatment was discontinued until intolerance of the side effects or the occurrence of disease progression. The clinical effect and adverse side effects of erlotinib were further observed, and the association between clinical characteristics and the response to erlotinib was also analyzed. Results Among the 72 patients, 1 patient achieved complete remission, 8 patients had partial remission, 10 had stable disease, and 7 had progressive disease, with a disease control rate of 72.22%. After a median follow-up time of 17 months （4 to 32 months）, the median survival time was 14.5 months （6.5-28.3 months）, and the median time to progression was 10.6 months （5-16.5 months）. Erlotinib resulted in a significantly higher rate of favorable response in female, non-smoking patients with adenocarcinoma than in male, smoking patients with squamous carcinoma （P〈0.05）. The occurrence of skin rash was not associated with the response to erlotinib in these patients （P〉0.05）. The most common drug-related adverse events included skin rash, diarrhea, hepatic dysfunction （GPT elevation）, nausea and vomiting, but mostly mild and well tolerable. Conclusion Erlotinib is safe and effective in the treatment of elderly patients with advanced NSCLC.

关 键 词：厄洛替尼 非小细胞癌 老年患者 

分 类 号：R734.2[医药卫生—肿瘤]